Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) Research & Development (2016 - 2025)

Angiodynamics (ANGO) has disclosed Research & Development for 15 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development changed N/A year-over-year to $7.8 million, compared with a TTM value of $29.0 million through Nov 2025, changed N/A, and an annual FY2024 reading of $31.5 million, changed N/A over the prior year.
  • Research & Development was $7.8 million for Q4 2025 at Angiodynamics, up from $6.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $9.1 million in Q2 2021 and bottomed at $6.4 million in Q3 2025.
  • Average Research & Development over 4 years is $7.6 million, with a median of $7.8 million recorded in 2025.
  • The sharpest move saw Research & Development increased 25.9% in 2021, then fell 16.6% in 2022.
  • Year by year, Research & Development stood at $8.2 million in 2021, then dropped by 16.6% to $6.8 million in 2022, then rose by 16.13% to $7.9 million in 2023, then fell by 2.18% to $7.8 million in 2025.
  • Business Quant data shows Research & Development for ANGO at $7.8 million in Q4 2025, $6.4 million in Q3 2025, and $7.9 million in Q3 2023.